M
Micha Fridman
Researcher at Tel Aviv University
Publications - 79
Citations - 1883
Micha Fridman is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Aminoglycoside & Antimicrobial. The author has an hindex of 23, co-authored 71 publications receiving 1450 citations. Previous affiliations of Micha Fridman include Harvard University & Technion – Israel Institute of Technology.
Papers
More filters
Journal ArticleDOI
Cationic Pillararenes Potently Inhibit Biofilm Formation without Affecting Bacterial Growth and Viability.
TL;DR: It is reported that water-soluble cationic pillararenes differing in the quaternary ammonium groups efficiently inhibited the formation of biofilms by clinically important Gram-positive pathogens.
Journal ArticleDOI
Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm.
Dongyeop Kim,Yuan Liu,Raphael I. Benhamou,Hiram Sanchez,Aurea Simon-Soro,Yong Li,Geelsu Hwang,Micha Fridman,David R. Andes,Hyun Koo +9 more
TL;DR: It is shown that the combination of clinically used topical antifungal fluconazole with povidone iodine (PI) can completely suppress C. albicans carriage and mixed-biofilm formation without increasing bacterial killing activity in vivo.
Journal ArticleDOI
6′′‐Thioether Tobramycin Analogues: Towards Selective Targeting of Bacterial Membranes
Ido M. Herzog,Keith D. Green,Yifat Berkov-Zrihen,Mark Feldman,Roee R. Vidavski,Anat Eldar-Boock,Ronit Satchi-Fainaro,Avigdor Eldar,Sylvie Garneau-Tsodikova,Micha Fridman +9 more
TL;DR: Three modes of action lead to bacterial resistance to AGs: reduction in the intracellular concentration of the antibiotics by efflux pump proteins or through reduced membrane permeability; structural modifications of the 16S ribosomal RNA leading to reduced target affinity; and deactivation by AG-modifying enzymes (AMEs).
Journal ArticleDOI
Exploring the Substrate Promiscuity of Drug-Modifying Enzymes for the Chemoenzymatic Generation of N-Acylated Aminoglycosides
Keith D. Green,Wei Chen,Wei Chen,Jacob L. Houghton,Jacob L. Houghton,Micha Fridman,Sylvie Garneau-Tsodikova,Sylvie Garneau-Tsodikova +7 more
TL;DR: The chemoenzymatic approach offers access to regioselectively N‐acylated aminoglycosides in quantities that allow testing of the antibacterial potential of the synthetic analogues making it possible to decide which molecules will be worth synthesizing on a larger scale.